QIAGEN Development Programs
Innovation in Sample and Assay Technologies
Sample & Assay Technologies
2
-QIAGEN Analyst and Investor Day, February 14, 2008
Safe Harbor Statement: Certain of the statements contained in this presentation may be
considered forward-looking statements within the meaning of Section 27A of the U.S. Securities
Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as
amended. To the extent that any of the statements contained herein relating to QIAGEN's
products and markets and operating results are forward-looking, such statements are based on
current expectations that involve a number of uncertainties and risks. Such uncertainties and
risks include, but are not limited to, risks associated with management of growth and
international operations (including the effects of currency fluctuations), variability of operating
results, the commercial development of the DNA sequencing, genomics and synthetic nucleic
acid-related markets, as well as the nucleic acid-based molecular diagnostics, applied testing
markets and genetic vaccination and gene therapy markets, competition, rapid or unexpected
changes in technologies, fluctuations in demand for QIAGEN's products (including fluctuations
for certain events including funding, budgets, and others), difficulties in successfully adapting
QIAGEN’s products to integrated solutions and producing such products, the ability of QIAGEN
to identify and develop new products and to differentiate its products from competitors, and the
integration of acquisitions of technologies and businesses. For further information, refer to the
discussion in reports that QIAGEN has filed with or furnished to the U.S. Securities and
Exchange Commission (SEC).
Forward Looking Statements
Agenda
Global R&D Organization
R&D Project Portfolio
QIAGEN Innovations
Sample & Assay Technologies
4
-QIAGEN Analyst and Investor Day, February 14, 2008
Global R&D
Competence Center in USA , Europe and Asia
North America
Assay & Systems
Development
Women's Health
(HPV, CT,NG)
siRNA
Application Labs
Applied Testing
Asia
Assay
Development
Application
Development
Europe
Application Development
Assay Development
Automated Systems
GEX; Proteomics; Corp. R&D
Systems Integration, Microfluidics
450 Scientists in Research & Development
Enabling Technologies for Sample Preparation in Life Science, Applied Testing, MDx
New Technology Development
Sample and Assay Technology, automated
Proteomics
Sample and Assay Technologies
Gene Silencing
Gene Expression
PCR and other Amplification Technologies
Diagnostic Sample Technology,
Assay Technology (HC&PCR), Content
DNA Handling, Purification
Genotyping, Storage, ...
Applications
Basic Research
Automated
Systems
Protein
Amplification &
modification
Gene Function
Molecular
Diagnostics
Application
DNA
Applied Testing
Molecular Diagnostics
Life Science Research
Pharma
Customer Segments
R&D Competence Center
Sample & Assay Technologies
6
-QIAGEN Analyst and Investor Day, February 14, 2008
hc (hybrid capture) 2.0 Add-ons
Next Generation Hybrid Capture
Screening Assay and Platform
NexGen Hybrid Capture Genotyping Assay
(„Probe Set“)
NexGen Plus Isothermal Amplification Assays
Fast HPV („dcHPV = developing countries“)
Diagnostic PCR Genotyping Assays
(Luminex-detection)
Custom PCR Genotyping Assays for Pharma
(Luminex-detection)
Products & Projects
RPA
(Regulated
Products)
Customer Segments
Women’s
Health
artus
B. pertussis LC PCR Kit RUO
Enterovirus LC RT-PCR Kit RUO
WNV LC RT-PCR Kit RUO
QIAplex Assays
Mvplex RUO
ResPlex III
HAI
Y.chromosome
MagAttract Virus+Blood IVD for EZ1
Cador
BVDV PCR Screening Kit RUO
BVDV PCR Subtyping Kit RUO
Taylorella, Rabies PCR Kits RUO
Portfolio Teams
Defining Product Applications within Customer Segment
Molecular Diagnostics
Molecular Diagnostics
Applied Testing
Pharma
Products & Projects
Customer Segments
Gene Function
Application
DNA
Gene Silencing
Genome siRNA Sets
miRNA assays + reagents
Gene Expression
AllPrep DNA/RNA 96
RNeasy 96 Plus
QuantiTect Multiplex Virus
Quantifast
Fastlane 1-step qRT-PCR
WTA (Whole Transcriptome Amplification)
EpiTect controls
REPLI-g FFPE DNA Kit
REPLI-g Fragmented DNA
SBTexcellerator HLA
QIAcube Applications
Automated
Systems
QIAcube
EZ1 CE IVD
QIAsymphony
Protein
Expression constructs on Gene Globe
Qxp crude lysate
NTA Univ. System
EasyXtal custom screens
Recombinant Membrane Protein Purification
Portfolio Teams
Defining Product Applications within Customer Segment
Life Science Research
Applied Testing
Sample & Assay Technologies
8
-QIAGEN Analyst and Investor Day, February 14, 2008
RPA
Gene
Expression
Application
DNA
Automated
Systems
Gene Function
Protein
R&D Budget Allocation
Women’s
Health
Basic Research
Reg./ IP &
Other
~30%
~15%
~15%
~5%
~3%
~3%
~3%
~2%
~20%
Agenda
Global R&D Organization
R&D Project Portfolio
QIAGEN Innovations
Sample & Assay Technologies
10
-QIAGEN Analyst and Investor Day, February 14, 2008
R&D Development Process:
Gate review & focus
168 Phase 0-2 Projects
PRC
PRC
Phase 2
Phase 3
Phase 4
Launch
PRC
Phase 0
Phase 1
PRC
PRC/
GRM
PT
58 Phase 3-5 Projects
Total Innovation Index
0,0
1,0
2,0
3,0
4,0
5,0
6,0
7,0
0,0
1,0
2,0
3,0
4,0
5,0
6,0
7,0
Market Attractivity
In
no
va
ti
on
G
ra
d
e
Project Portfolio
0
1
2
3
4
5
0
1
2
3
4
5
Project Performance
P
ro
je
c
t A
ttr
a
c
ti
v
e
n
e
s
s
58 Phase 3-5 Projects
Selection by Project Attractiveness & Performance
Project Portfolio
0
1
2
3
4
5
0
1
2
3
4
5
Project Performance
P
ro
ject
A
tt
ract
iven
ess
Project A
Project M
Project E
Project G
5,7
Project O
15
5,8
Project N
14
5,8
Project M
13
5,8
Project L
12
5,8
Projekt K
11
5,8
Project J
10
5,9
Project I
9
6,1
Project H
8
6,2
Project G
7
6,3
Project F
6
6,3
Project E
5
6,4
Project D
4
6,6
Project C
3
6,7
Project B
2
6,7
Project A
1
Project Score
Sample & Assay Technologies
12
-QIAGEN Analyst and Investor Day, February 14, 2008
Agenda
Global R&D Organization
R&D Project Portfolio
QIAGEN Innovations
Technology Roadmap: Planning the Future
Define the Field of Innovation
Identical Workflows In All Areas Of Life Sciences
Detection
Collection
Stabilization &
Storage
Enrichment
Purification
Content
Disruption
Amplification /
Modification
Bio-informatics
Applied Testing
Molecular Diagnostics
Life Science Research
Sample & Assay Technologies
14
-QIAGEN Analyst and Investor Day, February 14, 2008
Portfolio Team Output: 170 New Products
New Products Launched in 2005, 2006 and 2007
2007
2006
2005
REPLI-gKit
HotStar HiFidelity ; HotStarTaq Plus
REPLI-g Service
CompactPrep Plasmid
BIOROBOT Universal
EZ1 RNA Universal Tissue ; RNA Cell Mini
RNeasy Plus Mini Kit
QuantiTect Primer Assay
TurboCapture 8 / 96 / 384
AllPrep DNA/RNA Mini Kit
QuantiTect Multiplex RT-PCR
HiPerFect Transfection Reagent
Qproteome div.
PAXgene Blood RNA Kit CE, FDA & MDx
dNTP Mix
Appl. Pack
QuantiTect Rev.Transcription Kit (50)
FastLane Cell cDNA
HP Guaranteed siRNA ;
HP Flexible siRNA Design ;
HP GenomeWide siRNA ;
Customized siRNA Gene Sets
Customized siRNA Gene Sets ;
Genome Sets div.
Ni-NTA Fast Start ; BioSprint 15
EasyXpress div
LiquiChip Total Detection Kits div.
BioSprint 15 / 96 DNA Plant
HotStarTaq Plus Master Mix ; QIAGEN Fast Cycling ;
QIAGEN LongRange
QuickLyse Miniprep ; QIAGEN PlasmidAmp
MaXtract Low Density ; QIAGEN RNase Inhibitor ; IPTG ;
Nuclease-Free Water
EpiTect Bisulfite Kit, GelPilot
EZ1 DNA Investigator Kit
EZ1 Virus Mini Kit v2.0, TissueRuptor + TissueRuptor Probes
RNeasy Protect Saliva ; RNeasy FFPE ; RNeasy Protect Cell Mini
RNAprotect Cell Reagent, AllPrep RNA Protein Kit
FlexiPlate siRNA (tube + plate)
AllStars Neg. siRNA
miRNeasy Mini Kit ; miRNeasy 96 Kit
EasyXtal ; NeXtal, MassSpecSamplePrep
artus (new kits)
PAX Bone Marrow
Autopure Consumables, Puregene,
Autopure Instrument,
Generation
dNTP Set
REPLI-g UltraFast ; REPLI-g Screeing ; REPLI-g Mitochondrial
EZ1 DNA Investigator Card ; EZ1 VRS Card V2.0
App. Package, M48
QuantiTect Rev.Transcription Kit (200)
QuantiTect
Qproteome Plasma Membrane ; Qproteome Mitochondria ;
Qproteome FFPE Tissue
EasyXpress Insect Kit II ; EasyXpress Linear Template Kit Plus
EasyXpress pIX3.0 Vector Qproteome GlycoArray Kit
REPLI-g Fragmented DNA Kit
QuantiTect Multiplex Virus
REPLI-g (human-ID)
QIAcube
EZ1 CE IVD
QIAsymphonie
Quantifast
Fastlane 1-step qRT-PCR
WTA
Allprotect Reagent
Rat 1.0
miRNA assays + reagents
Genaco
MagAttract Virus+Blood IVD for EZ1 IVD
SBTexcellerator HLA
PAX xNA RNA Blood
QIAGEN Innovations
Examples of 2007 & 2008 Product Launches
Stabilization &
Storage
Purification
Amplification /
Modification
Detection
Content
BVDV PCR Screening Kit
QIAxcel
.
Reverse Transcriptase HotStart
Allprotect Tissue Reagent
QIAsymphony: Integrated Platform Technology
QIAcube & QIAsymphonySP
Sample & Assay Technologies
16
-QIAGEN Analyst and Investor Day, February 14, 2008
Allprotect Tissue Reagent
Features
Proprietary stabilization technology
Simultaneous preservation of DNA, RNA and
native proteins in one tissue sample
Immediate stabilization of harvested tissues
Shipment / storage
1 day at 37°C
up to 7days at 25°C
at least 12 months at 2-8°C
archiving at -20°C/-80°C
Compatible with “all” QIAGEN kits for target
purification
Wide range of downstream assays
Non-toxic
Stabilization &
Storage
Inn
ov
ati
on
Aw
ard
20
07
Bovine Viral Diarrhea Virus (BVDV)
Mucosal Disease MD
BVD Virus
Pest virus in cattle (also sheep and goats)
Closely related to
Border Disease Virus in sheep
Classical Swine Fever Virus
Infertility, abortion, congenital defects in calves
Persistent infected (PI) calves
constant source of reinfection
Mucosal Disease (MD), severe deadly infection
Not infectious to man
BVDV costs US$20 – US$160 per year and animal
US$ 97M & EU 85M cattle
Eradication programs in several countries
high awareness
Sample & Assay Technologies
18
-QIAGEN Analyst and Investor Day, February 14, 2008
Assay Technologies
Complete Solution From Sample To Result
Sample & Assay Technologies For BVD Testing
Sample Technologies
Automated sample prep
BioRobot Universal System
Manual sample prep
QIAamp Viral RNA Mini Kit
RNeasy Mini Kit
TissueLyser
cador
BVDV RT-PCR Kit
cador
BVDV Type 1/2 RT-PCR Kit
Additional veterinary assays
artus
M. paratuberculosis LC PCR Kit
artus
Influenza/H5 LC RT-PCR Kit
Further assays under development
Content
Product
FlexiPlate Gene Family updates
Human WG/DG siRNA Set v 4.0
AllStars hs cell death control
miScript additions
New DNA transfection reagent
Next generation Lipofection &
Nanofection
HiPerFect for miRNA
Online transfection protocols
TissueLyser II
Gene
Function
RNAi
ADNA
Protein
RPA
CompactPrep mega/giga
AIS
QIASymphony system
EZ1 Advanced
QIAxcel System/cartridges
QIAcube: additional protocols
FPLC Column extension NTA,
Strep-Tactin 5ml cartridges
QIAcard FTA
QIAsafe
VET BVDV PCR Screening Kit
VET BVDV PCR Subtyping Kit
VET Taylorella PCR Kit RUO
QIAamp DSP Virus Kit Modif. CD&US
Product
T1 Product Launches 2008
Sample & Assay Technologies
20
-QIAGEN Analyst and Investor Day, February 14, 2008
Selected Regulatory Approval Projects
Europe
HPV Genotyping
NextGen
QIAplex ResPlex II
Candor BVDV TM RT Kit
EZ1 upgrade virus
artus HCV RG
artus HIV RG
2011
2010
2009
2008
Year
Project
Submission
Running / planned project
Approval/Launch
510K Submission
Running / planned project
Approval/Launch (typically 12 months after submission)
Selected Regulatory Approval Projects
USA
HAI
DML 3000
HPV Genotyping
NextGen HPV Screening
QIAplex ResPlex II
HLA II
HLA I
artus CMV + EBV Taqman
artus EBV LC
artus CMV LC
2011
2010
2009
2008
Year
Project
PMA Submission
Sample & Assay Technologies
22
-QIAGEN Analyst and Investor Day, February 14, 2008
Selected Regulatory Approval Projects
Asia
Fast HPV
PG Biotech HIV Kit
PG Biotech HCV Kit
PG Biotech HBV Kit
Blood Screening Project
2011
2010
2009
2008
Year
Project
Submission
Running / planned project
Approval/Launch (typically 12 months after submission)
Agenda
Global R&D Organization
R&D Project Portfolio
QIAGEN Innovations
Sample & Assay Technologies
24
-QIAGEN Analyst and Investor Day, February 14, 2008
Technology Roadmap: Sample and Assay Technologies
Structure base on identical Workflows in all segments
Detection
Collection
Stabilization &
Storage
Enrichment
Purification
Content
Disruption
Amplification /
Modification
Bio-informatics
Sample T
e
chn
o
log
ies
Assa
y
T
e
chnol
ogies
Automated S
y
s
tems
Integrated Micr
os
y
s
tems
Applied Testing
Molecular Diagnostics
Life Science Research
Pharma
Implementation and
Ranking of 100 new
projects
Technology Roadmap Results
From 3000 Technologies to 100 Projects
Technology Overview
Technology Life Cycle
Norm Strategies
Evaluation of Relevance
Technology
Plan
Technology
Implementation
Overview on
>3000
Technologies
Approx.200
Technologies
identified as Relevant
For QIAGEN
Approx. 1000
Technologies
analyzed
t
-Kon
zepti
onell
„
1
2
3
4
5
Development Growth Maturity Decrease high
strong med tenable low QIAGEN’s Relative Technology Position
Industry average Opportunities for future advantage
Opportunities for present competitive advantage
Alarm signal for waste of ressources
Alarm signal for future Alarm signal for persent Alarm signal for
survival 1 21 52 5471 72
Life Cycle Stage of Technology Development Growth Maturity Decrease high
strong med tenable low QIAGEN’s Relative Technology Position
Industry average Opportunities for future advantage
Opportunities for present competitive advantage
Alarm signal for waste of ressources
Alarm signal for future Alarm signal for persent Alarm signal for
survival 1 21 52 5471 72
Life Cycle Stage of Technology
Emerging TechnologyPacing TechnologyKey Technology Base
Technology
DevelopmentGrowth Maturity Decrease
Technol
ogy
Perfor
mance
Technological Life Cycle (Technological Development Status)
Emerging TechnologyPacing TechnologyKey Technology Base
Technology
DevelopmentGrowth Maturity Decrease
Technol
ogy
Perfor
mance
Technological Life Cycle (Technological Development Status)
Inve st
Desinve st
low Technological Competitive Position
Technol ogy A ttrac tivenes s low high medium high medi um New Technologies (for QIAGEN) Core Technologies Obsolete Technologies 1 4 14 22 62 54 55 8 25 51 72 73 Inve st Desinve st low Technological Competitive Position
Technol ogy A ttrac tivenes s low high medium high medi um New Technologies (for QIAGEN) Core Technologies Obsolete Technologies 1 4 14 22 62 54 55 8 25 51 72 73 Process Technologies Magnetic bead handling …. Cont. Drive Technologies Drive control DC, step motor … Liquid Handling Fluid systems Air displacement systems .... Sensors Standard sensors1-D Barcode2-D Barcode……
Network / Data Integration LIMS Standards CMV XML Software Program software C++ …. Consumables Process cartridges and
reagents, tubes, tips
…… Usability HMI ….. Process Technologies Magnetic bead handling …. Cont. Drive Technologies Drive control DC, step motor … Liquid Handling Fluid systems Air displacement systems .... Sensors Standard sensors1-D Barcode2-D Barcode……
Network / Data Integration LIMS Standards CMV XML Software Program software C++ …. Consumables Process cartridges and
reagents, tubes, tips
…… Usability HMI …..
I
II
III
IV
V
Monitoring
Invest
“long ROI”
Optimization
“short ROI”
Disinvest
Resources
Pilot Projects
“little resources”
I
II
III
IV
V
Monitoring
Invest
“long ROI”
Optimization
“short ROI”
Disinvest
Resources
Pilot Projects
“little resources”
·Major decision pointDelay >60 daysDelay 30-60 daysOn track
Activities Year Quarter 2005 2006 2007 2008 Q3Q4 Q1Q2 Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4
Big uncertainty for launch date Next Step: Targets Launch on track
Forensic, Vet, Biodefense Kits on track, controls delayed
Estimated launch date: Q2/06 Next Step: Alternative to Venus Resource allocation critical! Millipore collaboration unclear
· · · · · · · · · · · · · · · · · · · 1.Xxx 2.Xxx 3.Xxx 4.Xxx 5.Xxx 6.Xxx 7.Xxx 8.Xxx 9.Xxx 10. Xxx 11. Xxx 12. Xxx 13. Xxx 14. Xxx 15. Xxx 16. Xxx 17. Xxx 18. Xxx 19. Xxx 20. Xxx
·Major decision pointDelay >60 daysDelay >60 daysDelay 30-60 daysDelay 30-60 daysOn trackOn track
Activities Year Quarter 2005 2006 2007 2008 Q3Q4 Q1Q2 Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4
Big uncertainty for launch date Next Step: Targets Launch on track
Forensic, Vet, Biodefense Kits on track, controls delayed
Estimated launch date: Q2/06 Next Step: Alternative to Venus Resource allocation critical! Millipore collaboration unclear Big uncertainty for launch date Next Step: Targets Launch on track
Forensic, Vet, Biodefense Kits on track, controls delayed
Estimated launch date: Q2/06 Next Step: Alternative to Venus Resource allocation critical! Millipore collaboration unclear Big uncertainty for launch date Next Step: Targets Launch on track
Forensic, Vet, Biodefense Kits on track, controls delayed
Estimated launch date: Q2/06 Next Step: Alternative to Venus Resource allocation critical! Millipore collaboration unclear
· · · · · · · · · · · · · · · · · · · 1.Xxx 2.Xxx 3.Xxx 4.Xxx 5.Xxx 6.Xxx 7.Xxx 8.Xxx 9.Xxx 10. Xxx 11. Xxx 12. Xxx 13. Xxx 14. Xxx 15. Xxx 16. Xxx 17. Xxx 18. Xxx 19. Xxx 20. Xxx
